The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy
Abstract
Cancer immunotherapies that harness the body's immune system to combat tumors have received extensive attention and become mainstream strategies for treating cancer. Despite promising results, some problems remain, such as the limited patient response rate and the emergence of severe immune‐related adverse effects. For most patients, the therapeutic efficacy of cancer immunotherapy is mainly limited by the immunosuppressive tumor microenvironment (TME). To overcome such obstacles in the TME, the immunomodulation of immunosuppressive factors and therapeutic immune cells (e.g., T cells and antigen‐presenting cells) should be carefully designed and evaluated. Nanoengineered synthetic immune niches have emerged as highly customizable platforms with a potent capability for reprogramming the immunosuppressive TME. Here, recent developments in nano‐biomaterials that are rationally designed to modulate the immunosuppressive TME in a spatiotemporal manner for enhanced cancer immunotherapy which are rationally designed to modulate the immunosuppressive TME in a spatiotemporal manner for enhanced cancer immunotherapy are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: FoxP3 Acts as a Cotranscription Factor with STAT3 in Tumor-Induced Regulatory T Cells
Hossain, D. M. S., Panda, A. K., Manna, A., Mohanty, S., Bhattacharjee, P., Bhattacharyya, S., Saha, T., Chakraborty, S., Kar, R. K., Das, T., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.005 · Cited by 116
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Rooijen, N. V., & Sanders, A. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90012-4 · Cited by 1,779
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
Yang, G., Xu, L., Chao, Y., Xu, J., Sun, X., Wu, Y., Peng, R., & Liu, Z. (2017) · Nature Communications · doi:10.1038/s41467-017-01050-0 · Cited by 1,477
Regulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Nanoparticles target distinct dendritic cell populations according to their size
Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P., & Bachmann, M. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737984 · Cited by 1,289
Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220
Hallmarks of cancer: Interactions with the tumor stroma
Pietras, K., & Östman, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.045 · Cited by 1,141
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,056
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy
Yu, M. K., Park, J., & Jon, S. (2012) · Theranostics · doi:10.7150/thno.3463 · Cited by 883
Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013) · Immunology · doi:10.1111/imm.12036 · Cited by 815
Epigenetic modifications as therapeutic targets
Kelly, T. K., De Carvalho, D. D., & Jones, P. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1678 · Cited by 793
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b05030 · Cited by 784
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Min, Y., Roche, K. C., Tian, S., Eblan, M. J., McKinnon, K. P., Caster, J. M., Chai, S., Herring, L. E., Zhang, L., Zhang, T., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.113 · Cited by 701
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
Toxicities of Immunotherapy for the Practitioner
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0379 · Cited by 650
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Zeisberger, S. M., Odermatt, B., Marty, C., Zehnder-Fjällman, A. H. M., Ballmer-Hofer, K., & Schwendener, R. A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603240 · Cited by 623
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Impact of the physical microenvironment on tumor progression and metastasis
Spill, F., Reynolds, D. S., Kamm, R. D., & Zaman, M. H. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.007 · Cited by 581
Wang, C., Xu, L., Liang, C., Xiang, J., Peng, R., & Liu, Z. (2014) · Advanced Materials · doi:10.1002/adma.201402996 · Cited by 566
Kim, J., Li, W. A., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 526
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4323 · Cited by 504
Activation of fibroblasts in cancer stroma
Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 494
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Kusmartsev, S. A., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E. M., Lush, R. M., & Gabrilovich, D. I. (2003) · PubMed · Cited by 460
Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452
Lynn, G. M., Laga, R., Darrah, P. A., Ishizuka, A. S., Balaci, A. J., Dulcey, A. E., Pechar, M., Pola, R., Gerner, M. Y., Yamamoto, A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3371 · Cited by 440
Lu, J., Liu, X., Liao, Y.-P., Salazar, F., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 440
Biopolymer implants enhance the efficacy of adoptive T-cell therapy
Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2015) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 439
Immune resistance orchestrated by the tumor microenvironment
Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437
Infection-mimicking materials to program dendritic cells in situ
Ali, O. A., Huebsch, N., Cao, L., Dranoff, G., & Mooney, D. J. (2009) · Nature Materials · doi:10.1038/nmat2357 · Cited by 434
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Bezu, L., Gomes-de-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 390
Sul, J., Blumenthal, G. M., Jiang, X., He, K., Keegan, P., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0498 · Cited by 359
Ye, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z. (2016) · ACS Nano · doi:10.1021/acsnano.6b04989 · Cited by 339
Qian, Y., Qiao, S., Dai, Y., Xu, G., Dai, B., Lu, L., Yu, X., Luo, Q., & Zhang, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b05465 · Cited by 333
Tumour macrophages as potential targets of bisphosphonates
Rogers, T. L., & Holen, I. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-177 · Cited by 324
Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival
Cieslewicz, M., Tang, J., Yu, J. L., Cao, H., Zavaljevski, M., Motoyama, K., Lieber, A., Raines, E. W., & Pun, S. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312197110 · Cited by 314
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells
Huang, B., Abraham, W. D., Zheng, Y., Bustamante López, S. C., Luo, S. S., & Irvine, D. J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5447 · Cited by 312
van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 309
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Gazzaniga, S., Bravo, A. I., Guglielmotti, A., van Rooijen, N., Maschi, F., Vecchi, A., Mantovani, A., Mordoh, J., & Wainstok, R. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700827 · Cited by 302
Cohen, N., Shani, O., Raz, Y., Sharon, Y., Hoffman, D., Abramovitz, L., & Erez, N. (2017) · Oncogene · doi:10.1038/onc.2017.65 · Cited by 292
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
Xu, Z., Wang, Y., Zhang, L., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn500216y · Cited by 284
Reversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
Kusmartsev, S., Su, Z., Heiser, A., Dannull, J., Eruslanov, E., Kübler, H., Yancey, D., Dahm, P., & Vieweg, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0165 · Cited by 284
Tailoring nanoparticle designs to target cancer based on tumor pathophysiology
Sykes, E. A., Dai, Q., Sarsons, C. D., Chen, J., Rocheleau, J. V., Hwang, D. M., Zheng, G., Cramb, D. T., Rinker, K. D., & Chan, W. C. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521265113 · Cited by 281
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
Goldberg, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.037 · Cited by 278
Cheng, J.-T., Deng, Y.-N., Yi, H.-M., Wang, G.-Y., Fu, B.-S., Chen, W.-J., Liu, W., Tai, Y., Peng, Y.-W., & Zhang, Q. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.7 · Cited by 267
Venkatesan, P., Puvvada, N., Dash, R., Prashanth Kumar, B. N., Sarkar, D., Azab, B., Pathak, A., Kundu, S. C., Fisher, P. B., & Mandal, M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.027 · Cited by 262
Zhao, X., Yang, K., Zhao, R., Ji, T., Wang, X., Yang, X., Zhang, Y., Cheng, K., Liu, S., Hao, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.032 · Cited by 256
Song, Q., Yin, Y., Shang, L., Wu, T., Zhang, D., Kong, M., Zhao, Y., He, Y., Tan, S., Guo, Y., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03186 · Cited by 254
In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice
Ali, O. A., Emerich, D., Dranoff, G., & Mooney, D. J. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000359 · Cited by 246
A carbon nanotube–polymer composite for T-cell therapy
Fadel, T. R., Sharp, F. A., Vudattu, N., Ragheb, R., Garyu, J., Kim, D., Hong, E., Li, N., Haller, G. L., Pfefferle, L. D., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.154 · Cited by 240
Conde, J., Bao, C., Tan, Y., Cui, D., Edelman, E. R., Azevedo, H. S., Byrne, H. J., Artzi, N., & Tian, F. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201501283 · Cited by 238
Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications
Moysan, E., Bastiat, G., & Benoit, J.-P. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300370t · Cited by 225
Xu, L., Stevens, J., Hilton, M. B., Seaman, S., Conrads, T. P., Veenstra, T. D., Logsdon, D., Morris, H., Swing, D. A., Patel, N. L., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008455 · Cited by 223
Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation
Li, S.-Y., Liu, Y., Xu, C.-F., Shen, S., Sun, R., Du, X.-J., Xia, J.-X., Zhu, Y.-H., & Wang, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.044 · Cited by 222
Miao, L., Newby, J. M., Lin, C. M., Zhang, L., Xu, F., Kim, W. Y., Forest, M. G., Lai, S. K., Milowsky, M. I., Wobker, S. E., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b02776 · Cited by 221
Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors
Miao, L., Liu, Q., Lin, C. M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W. Y., & Huang, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0866 · Cited by 215
Sato, K., Sato, N., Xu, B., Nakamura, Y., Nagaya, T., Choyke, P. L., Hasegawa, Y., & Kobayashi, H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6843 · Cited by 213
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles
Stephan, M. T., Stephan, S. B., Bak, P., Chen, J., & Irvine, D. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.029 · Cited by 209
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity
Li, Y., Fang, M., Zhang, J., Wang, J., Song, Y., Shi, J., Li, W., Wu, G., Ren, J., Wang, Z., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1074374 · Cited by 203
Fransen, M. F., van der Sluis, T. C., Ossendorp, F., Arens, R., & Melief, C. J. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0781 · Cited by 200
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
Héninger, E., Krueger, T. E. G., & Lang, J. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00029 · Cited by 194
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
Chen, Y., Xia, R., Huang, Y., Zhao, W., Li, J., Zhang, X., Wang, P., Venkataramanan, R., Fan, J., Xie, W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13443 · Cited by 190
Epigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 189
Predina, J., Eruslanov, E., Judy, B., Kapoor, V., Cheng, G., Wang, L.-C., Sun, J., Moon, E. K., Fridlender, Z. G., Albelda, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211850110 · Cited by 188
Shen, S., Li, H.-J., Chen, K.-G., Wang, Y.-C., Yang, X.-Z., Lian, Z.-X., Du, J.-Z., & Wang, J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b01193 · Cited by 186
Synthetic immune niches for cancer immunotherapy
Weiden, J., Tel, J., & Figdor, C. G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.89 · Cited by 174
Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells
Jensen, M. C., & Riddell, S. R. (2013) · Immunological Reviews · doi:10.1111/imr.12139 · Cited by 170
Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
Kosmides, A. K., Sidhom, J.-W., Fraser, A., Bessell, C. A., & Schneck, J. P. (2017) · ACS Nano · doi:10.1021/acsnano.6b08152 · Cited by 170
Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy
Huang, Z., Zhang, Z., Jiang, Y., Zhang, D., Chen, J., Dong, L., & Zhang, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.013 · Cited by 169
Zhan, X., Jia, L., Niu, Y., Qi, H., Chen, X., Zhang, Q., Zhang, J., Wang, Y., Dong, L., & Wang, C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.09.007 · Cited by 161
EGF Receptor-Targeted Nanocarriers for Enhanced Cancer Treatment
Master, А. M., & Gupta, A. S. (2012) · Nanomedicine · doi:10.2217/nnm.12.160 · Cited by 161
Tumor cell lysates as immunogenic sources for cancer vaccine design
González, F. E., Gleisner, A., Falcón-Beas, F., Osorio, F., López, M. N., & Salazar-Onfray, F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.982996 · Cited by 160
Huo, M., Zhao, Y., Satterlee, A., Wang, Y., Xu, Y., & Huang, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.013 · Cited by 159
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
Ishihara, J., Fukunaga, K., Ishihara, A., Larsson, H. M., Potin, L., Hosseinchi, P., Galliverti, G., Swartz, M. A., & Hubbell, J. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0401 · Cited by 158
Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma
Takahashi, H., Sakakura, K., Kawabata‐Iwakawa, R., Rokudai, S., Toyoda, M., Nishiyama, M., & Chikamatsu, K. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1742-0 · Cited by 157
Perica, K., Bieler, J. G., Schütz, C., Varela, J. C., Douglass, J., Skora, A. D., Chiu, Y., Oelke, M., Kinzler, K. W., Zhou, S., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b02829 · Cited by 153
Dheilly, E., Moine, V., Broyer, L., Salgado-Pires, S., Johnson, Z., Papaioannou, A., Cons, L., Calloud, S., Majocchi, S., Nelson, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.006 · Cited by 151
Sasso, M. S., Lollo, G., Pitorre, M., Solito, S., Pinton, L., Valpione, S., Bastiat, G., Mandruzzato, S., Bronte, V., Marigo, I., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.010 · Cited by 150
Phuengkham, H., Song, C., Um, S. H., & Lim, Y. T. (2018) · Advanced Materials · doi:10.1002/adma.201706719 · Cited by 144
Self-citationGollob, J., Sciambi, C. J., Peterson, B. L., Richmond, T. M., Thoreson, M., Moran, K., Dressman, H. K., Jelínek, J., & Issa, J. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0883 · Cited by 133
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer
Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C. M., Goodwin, T. J., Dorosheva, O., Liu, R., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01786 · Cited by 133
Epigenetic regulation of immune escape genes in cancer
Tomasi, T. B., Magner, W. J., & Khan, A. N. H. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0164-4 · Cited by 132
Murakami, M., Ernsting, M. J., Undzys, E., Holwell, N., Foltz, W. D., & Li, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0062 · Cited by 131
Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
Baay, M. F. D., Brouwer, A., Pauwels, P., Peeters, M., & Lardon, F. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/565187 · Cited by 130
Abele, R., Clavel, M., Dodion, P. F., Bruntsch, U., Gundersen, S., Smyth, J., Renard, J., Glabbeke, M. M. V., & Pinedo, H. M. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90060-5 · Cited by 120
Lei, C., Liu, P., Chen, B., Mao, Y., Engelmann, H. E., Shin, Y., Jaffar, J., Hellström, I., Liu, J., & Hellström, K. E. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102414t · Cited by 117
TGF Beta Inhibition for Cancer Therapy
Saunier, E. F., & Akhurst, R. J. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906778742460 · Cited by 114
Advances in personalized cancer immunotherapy
Kakimi, K., Karasaki, T., Matsushita, H., & Sugie, T. (2016) · Breast Cancer · doi:10.1007/s12282-016-0688-1 · Cited by 112
Zhang, H., Li, X., Ding, J., Xu, H., Dai, X., Hou, Z., Zhang, K., Sun, K., & Sun, W. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.11.034 · Cited by 111
Talimogene Laherparepvec for the Treatment of Advanced Melanoma
Ott, P. A., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2709 · Cited by 111
Zhang, J., Miao, L., Guo, S., Zhang, Y., Zhang, L., Satterlee, A., Kim, W. Y., & Huang, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.016 · Cited by 110
IDO inhibitors move center stage in immuno-oncology
Sheridan, C. (2015) · Nature Biotechnology · doi:10.1038/nbt0415-321 · Cited by 110
Chen, Q., Xu, L., Chen, J., Yang, Z., Liang, C., Yang, Y., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.021 · Cited by 104
Epigenetic drugs as immunomodulators for combination therapies in solid tumors
Sigalotti, L., Fratta, E., Coral, S., & Maio, M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.015 · Cited by 102
Karpf, A. R. (2006) · Epigenetics · doi:10.4161/epi.1.3.2988 · Cited by 99
In VivoTargeting of Intratumor Regulatory T Cells Using PEG-Modified Single-Walled Carbon Nanotubes
Sacchetti, C., Rapini, N., Magrini, A., Cirelli, E., Stefano Bellucci, A., Mattei, M., Rosato, N., Bottini, N., & Bottini, M. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400070q · Cited by 98
Cytokine-Release Syndrome: Overview and Nursing Implications
Breslin, S. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.s1.37-42 · Cited by 85
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
Cousin, S., & Italiano, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2569 · Cited by 83
Zhao, Y., Huo, M., Xu, Z., Wang, Y., & Huang, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.053 · Cited by 80
Noh, Y., Kim, S., Kim, J., Kim, S., Ryu, J., Kim, I., Lee, E. J., Um, S. H., & Lim, Y. T. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201605398 · Cited by 78
Self-citationJeanbart, L., Kourtis, I. C., van der Vlies, A. J., Swartz, M. A., & Hubbell, J. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1702-8 · Cited by 68
Zhu, Y., Wen, L., Shao, S., Tan, Y., Meng, T., Yang, X., Liu, Y., Liu, X., Yuan, H., & Hu, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.023 · Cited by 66
Key Role of Macrophages in the Pathogenesis of CD18 Hypomorphic Murine Model of Psoriasis
Wang, H., Peters, T., Sindrilaru, A., & Scharffetter‐Kochanek, K. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.43 · Cited by 63
Su, X., Wang, Z., Li, L., Zheng, M., Zheng, C., Gong, P., Zhao, P., Ma, Y., Tao, Q., & Cai, L. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300675c · Cited by 63
Moghaddam, L. K., Paschepari, S. R., Zaimy, M. A., Abdalaian, A., & Jebali, A. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.38 · Cited by 61
Makkouk, A., Joshi, V. B., Wongrakpanich, A., Lemke-Miltner, C. D., Gross, B., Salem, A. K., & Weiner, G. J. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9676-6 · Cited by 59
Mohamed, E. A., Zhao, Y., Meshali, M. M., Remsberg, C. M., Borg, T. M., Foda, A. M. M., Takemoto, J. K., Sayre, C. L., Martinez, S. E., Davies, N. M., et al. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23265 · Cited by 56
Li, J., Gong, C., Feng, X., Zhou, X., Xu, X., Xie, L., Wang, R., Zhang, D., Wang, H., Deng, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033860 · Cited by 54
Zhang, B., Jin, K., Jiang, T., Wang, L., Shen, S., Luo, Z., Tuo, Y., Liu, X., Hu, Y., & Pang, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-09520-7 · Cited by 49
Engel, A., Svane, I. M., Mouritsen, S., Rygaard, J., Clausen, J. T., & Werdelin, O. (1996) · Apmis · doi:10.1111/j.1699-0463.1996.tb04923.x · Cited by 48
Šímová, J., Polláková, V., Indrová, M., Mikyšková, R., Bieblová, J., Štěpánek, I., Bubenik, J., & Reiniš, M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.428 · Cited by 47
Localized Multi‐Component Delivery Platform Generates Local and Systemic Anti‐Tumor Immunity
Acharya, A. P., Sinha, M. K., Ratay, M. L., Ding, X., Balmert, S. C., Workman, C. J., Wang, Y., Vignali, D. A. A., & Little, S. R. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201604366 · Cited by 46
Kozar, K., Kamiński, R., Świtaj, T., Ołdak, T., Machaj, E. K., Wysocki, P. J., Mackiewicz, A. A., Lasek, W., Jakóbisiak, M., & Gołąb, J. (2003) · PubMed · Cited by 45
Gao, X., Liu, Y., Deeb, D., Liu, P., Liu, A., Arbab, A. S., & Gautam, S. C. (2013) · PubMed · Cited by 43
Branca, M. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3690 · Cited by 43
Shen, H., Sun, T., Hoang, H. H., Burchfield, J. S., Hamilton, G. F., Mittendorf, E. A., & Mauro Ferrari, B. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.002 · Cited by 37
Wang, Y., Wang, H., Lv, X., Liu, C., Qi, L., Song, X., & Yu, A. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201300295 · Cited by 24
Molavi, O., Ma, Z., Hamdy, S. I., Lavasanifar, A., & Samuel, J. (2008) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923970802380452 · Cited by 21
Cited by
Targeting STAT3 in Cancer Immunotherapy
Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,050
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy
Jiang, Q., Wang, K., Zhang, X., Ouyang, B., Liu, H., Pang, Z., & Yang, W. (2020) · Small · doi:10.1002/smll.202001704 · Cited by 426
Artificial Enzyme Catalyzed Cascade Reactions: Antitumor Immunotherapy Reinforced by NIR‐II Light
Wen, M., Ouyang, J., Wei, C., Li, H., Chen, W., & Liu, Y. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909729 · Cited by 269
Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy
Fu, S., Li, G., Zang, W., Zhou, X., Shi, K., & Zhai, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.012 · Cited by 266
Metadata
- Authors
- Phuengkham, H., Ren, L., Shin, I. W., & Lim, Y. T.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2019-02-18
- Volume
- 31
- Issue
- 34
- Pages
- e1803322-e1803322
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2917780715
- Cited by
- 306
- References
- 159
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.